Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Siliq

EU flag

EC fines J&J and Novartis in pay-for-delay case

Says companies delayed entry of generic painkiller

- PMLiVE

FDA panel backs Takeda’s inflammatory bowel disease drug

Vedolizumab on course for US approval to treat Crohn’s disease and ulcerative colitis

- PMLiVE

Novartis’ Tasigna tops Glivec in long-term trial

Boost ahead of patent expiry for leukaemia drug

FDA reins in Google-backed genetics company 23andMe

Health-related genetic test service put on hold pending US regulatory review

- PMLiVE

Auxilium’s Xiaflex cleared in US for erection disorder

FDA approval to treat Peyronie's disease

Novartis building

Novartis myeloma drug clears phase III trial

Panobinostat on course to be first in new class of treatment for bone marrow cancer

- PMLiVE

Baxter re-files HyQvia for immunodeficiency in US

Pharma company provides FDA with more data

- PMLiVE

FDA backs new formulation of Noxafil

Merck wins US approval for delayed-release version of anti-infective

Novartis building

Novartis sets sights on eliminating leprosy

Throws weight behind meeting WHO's 2020 eradication goal

Novartis building

Scientists finds new drug target for malaria

Novartis and academics identify new class of medicines to treat all stages of infection

Valeant appoints company group chairman

Ari Kellen joins from McKinsey & Company

- PMLiVE

FDA lifts restrictions on Avandia use

US regulator says GSK’s diabetes drug does not increase heart attack risk

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links